1. Researchers Address Clinical Challenge in Fertility-Preserving Treatment for Endometrioid Endometrial Carcinoma
The incidence of endometrial cancer is rising steadily, particularly among younger women who have not yet had children. Standard surgical treatment for the disease results in permanent infertility, making fertility-preserving therapy critically important for these young patients. According to published literature, more than 30% of patients show insensitivity to progestin-based treatment regimens. Currently, no reliable method exists to predict a patient's response to progestin therapy. In response to this urgent clinical need, researchers have successfully resolved this medical challenge.
2. Research Team Builds Patient-Derived Tumor Model to Advance Endometrioid Endometrial Carcinoma Study
By gaining a deep understanding of the features of endometrioid endometrial carcinoma (EEC), the research team has successfully constructed patient-derived tumor cell clusters (PTCs) from individuals with EEC. This model closely reproduces the histological, cytological, and genomic characteristics of primary tumors, offering an excellent in vitro model for future research.
3. Novel Imaging Technique Reveals Biomarker for Progesterone Insensitive in Endometrioid Endometrial Carcinoma
Using hyperspectral stimulated Raman scattering (hSRS) microscopy—which offers high molecular selectivity and submicron spatial resolution—researchers made a surprising discovery: abnormal accumulation of cholesterol esters (CEs) in patient-derived tumor cell clusters (PTCs) from individuals with progesterone‑insensitive (PI) EEC. The cholesterol ester percentage (CEP) was identified as an independent biomarker capable of distinguishing progesterone‑insensitive patients from those who are progesterone‑sensitive (PS). Moreover, longitudinal changes in CEP showed a strong correlation with clinical treatment response.
4. Combination Therapy Dramatically Improves Outcomes in Progesterone Insensitive Endometrioid Endometrial Carcinoma; First "Statin Baby" Born
In a more significant finding, a retrospective clinical cohort study confirmed that among progesterone‑insensitive (PI) patients defined by cholesterol ester percentage (CEP) criteria, combination therapy with progestin and a statin substantially increased the six‑month complete remission rate—from 7.69% with progestin alone to 66.67% with the combination therapy. Excitingly, this combined treatment strategy has already helped one PI patient give birth to a healthy "statin baby."
The results are of high quality and exciting, as they provide a clinically actionable assay and findings that may advance precision management of endometrial carcinoma, which remains a major unmet clinical need globally. The impact on fertility preservation is particularly significant.
Science Bulletin